Young Joo Min

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 434 citations

Medicine, Oncology, Pharmacology +9

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement

Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee et al. · Journal of Clinical Oncology · 2017 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim et al. · Journal of Clinical Oncology · 2015 · 258 citations · Full text

Medicine, Oncology, Radiation Oncology +17

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku et al. · Clinical Cancer Research · 2019 · 212 citations · Full text

Medicine, Oncology, Pharmacology +17